Deciphera Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

PDF File

WALTHAM, Mass.--(BUSINESS WIRE)--May 27, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 2:00 PM ET. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCKTM is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of 4L Gastrointestinal Stromal Tumors. For more information, please visit the company’s website at www.deciphera.com.

Investor Relations:
Jen Robinson
Deciphera Pharmaceuticals, Inc
jrobinson@deciphera.com
781-906-1112

Media:
David Rosen
Argot Partners
David.Rosen@argotpartners.com
212-600-1902

Source: Deciphera Pharmaceuticals, Inc.